A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Solid Tumors
Interventions: DRUG: Bemarituzumab
Sponsor: Amgen